TY - JOUR
T1 - Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders
AU - International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
AU - Ciccarelli, Olga
AU - Cohen, Jeffrey A.
AU - Reingold, Stephen C.
AU - Weinshenker, Brian G.
AU - Amato, Maria Pia
AU - Banwell, Brenda
AU - Barkhof, Frederik
AU - Bebo, Bruce
AU - Becher, Burkhard
AU - Bethoux, François
AU - Brandt, Alexander
AU - Brownlee, Wallace
AU - Calabresi, Peter
AU - Chatway, Jeremy
AU - Chien, Claudia
AU - Chitnis, Tanuja
AU - Comi, Giancarlo
AU - Correale, Jorge
AU - De Sèze, Jerome
AU - De Stefano, Nicola
AU - Fazekas, Franz
AU - Flanagan, Eoin
AU - Freedman, Mark
AU - Fujihara, Kazuo
AU - Galetta, Steven
AU - Goldman, Myla
AU - Greenberg, Benjamin
AU - Hartung, Hans Peter
AU - Hemmer, Bernhard
AU - Henning, Anke
AU - Izbudak, Izlem
AU - Kappos, Ludwig
AU - Lassmann, Hans
AU - Laule, Cornelia
AU - Levy, Michael
AU - Lublin, Fred
AU - Lucchinetti, Claudia
AU - Lukas, Carsten
AU - Marrie, Ruth Ann
AU - Miller, Aaron
AU - Miller, David
AU - Montalban, Xavier
AU - Mowry, Ellen
AU - Ourselin, Sebastien
AU - Paul, Friedemann
AU - Pelletier, Daniel
AU - Ranjeva, Jean Philippe
AU - Reich, Daniel
AU - Reingold, Stephen
AU - Rocca, Maria Assunta
N1 - Funding Information:
This Review was motivated by the International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders held on May 18–20, 2017 in Berlin, Germany. The Conference was convened under the auspices of the International Advisory Committee on Clinical Trials in Multiple Sclerosis. Both the Committee and the Conference were sponsored and supported by the US National Multiple Sclerosis Society and the European Committee for Treatment and Research in Multiple Sclerosis. All Conference participants ( appendix ) were provided with the opportunity to review a draft of the manuscript and suggest revisions before finalisation. There was no involvement of the sponsors in the design of the Conference, or in the collection, analysis, or interpretation of data involved in the publication, nor in the writing of the manuscript, nor the decision to submit it for publication. We thank Alex Róvira (Unidad de Resonancia Magnética, Hospital Universitari Vall d'Hebron, Barcelona, Spain) for providing figure 1 , Eoin Flanagan (Department of Neurology, Mayo Clinic, Rochester, MN, USA) for providing figure 3 , and Claudia Lucchinetti (Department of Neurology, Mayo Clinic, Rochester, MN, USA) for providing figure 4 .
Funding Information:
OC reports grants from the MS Society of Great Britain & Northern Ireland, National Institute for Health Research University College London Hospital Biomedical Research Centre (NIHR UCLH BRC), National Multiple Sclerosis Society, NIHR, the Spinal Cord Research Foundation, Rosetrees Trust, Progressive MS Alliance, Bioclinica & GE Neuro, and EU-H2020; has received consultancy fees from Novartis, Teva Pharmaceutical Industries, Roche, Biogen, and Merck; personal fees and other payments from Neurology ; and non-financial and other support from the Multiple Sclerosis Journal . JAC reports consultancy fees from Adamas Pharmaceuticals, Celgene, Convelo, EMD Serono, Novartis, and PendoPharm; and speaking fees from Mylan and Synthon. SCR reports personal fees from the National Multiple Sclerosis Society, European Committee for Treatment and Research in Multiple Sclerosis, Ionis Pharmaceuticals, Opexa Therapeutics, Teva Pharmaceutical Industries, and TG Therapeutics; personal fees and other payments from F Hoffmann-LaRoche, Medday Pharmaceuticals SA, MedImmune Inc, Merck Serono, Novartis, and Observatoire Français pour la Sclérosis en Plaques; and non-financial support from Scientific and Clinical Review Associates LLC. BGW reports personal fees from Novartis, MedImmune, Alexion, Caladrius Biosciences, Biogen-Idec, Roivant, and Brainstorm Therapeutics; has a patent of NMO-IgG for diagnosis of neuromyelitis optica with royalties paid to RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr Volkmann und Kollegen GbR.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/2
Y1 - 2019/2
N2 - Spinal cord involvement is an important cause of disability in patients with multiple sclerosis or neuromyelitis optica spectrum disorders (NMOSDs). Multiple sclerosis and NMOSDs can be distinguished from other disorders that cause myelopathy by results from laboratory and radiological investigations. However, limitations in the sensitivity and specificity of spinal cord imaging and poor correlation with disability megasures have impeded the understanding of the relationship between spinal cord involvement and clinical manifestations. Nevertheless, studies of the pathological features of multiple sclerosis and NMOSDs have shown that quantitatively different mechanisms lead to differences in clinical course and pattern of accrual of permanent disability in the two disorders. Better understanding of these mechanisms is necessary to develop more informative clinical measures, electrophysiological methods, fluid biomarkers, and imaging techniques to detect and monitor spinal cord involvement in the diagnosis and management of patients with multiple sclerosis or NMOSDs, and as outcome measures in clinical trials.
AB - Spinal cord involvement is an important cause of disability in patients with multiple sclerosis or neuromyelitis optica spectrum disorders (NMOSDs). Multiple sclerosis and NMOSDs can be distinguished from other disorders that cause myelopathy by results from laboratory and radiological investigations. However, limitations in the sensitivity and specificity of spinal cord imaging and poor correlation with disability megasures have impeded the understanding of the relationship between spinal cord involvement and clinical manifestations. Nevertheless, studies of the pathological features of multiple sclerosis and NMOSDs have shown that quantitatively different mechanisms lead to differences in clinical course and pattern of accrual of permanent disability in the two disorders. Better understanding of these mechanisms is necessary to develop more informative clinical measures, electrophysiological methods, fluid biomarkers, and imaging techniques to detect and monitor spinal cord involvement in the diagnosis and management of patients with multiple sclerosis or NMOSDs, and as outcome measures in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85060049167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060049167&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(18)30460-5
DO - 10.1016/S1474-4422(18)30460-5
M3 - Review article
C2 - 30663608
AN - SCOPUS:85060049167
VL - 18
SP - 185
EP - 197
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 2
ER -